{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:32Z","timestamp":1790983112147,"version":"4.1.0"},"reference-count":23,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Sage Open Medical Case Reports"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Drug-induced lupus erythematosus (DIL) is an uncommon condition that mimics systemic lupus erythematosus (SLE) and accounts for approximately 10%\u201312% of SLE cases. Numerous drugs have been implicated, most commonly hydralazine, procainamide, isoniazid, and certain antiepileptics. Levetiracetam has rarely been associated with SLE. We describe the first known possible pediatric case of suspected levetiracetam-induced lupus erythematosus. A previously healthy 6-year-old girl developed thrombocytopenia, neutropenia, anemia, generalized lymphadenopathy, and a petechial rash several months after initiating levetiracetam therapy for absence seizures. Extensive infectious and oncologic investigations, including a bone marrow biopsy and an excisional lymph node biopsy were unremarkable. Given the temporal association with levetiracetam exposure, the presence of clinical features consistent with DIL, and a serological pattern suggestive of DIL, the drug was discontinued, and the patient was treated with corticosteroids, intravenous immunoglobulin, and hydroxychloroquine. She demonstrated rapid clinical and biochemical improvement. Although distinguishing DIL from early SLE remains challenging and no definitive diagnostic criteria exist, this case met several proposed features of DIL and scored as a possible adverse drug reaction on the Naranjo scale. This report expands the spectrum of levetiracetam-associated adverse effects and highlights the need for clinicians to consider DIL in pediatric patients even when receiving drugs with generally favorable safety profiles.<\/jats:p>","DOI":"10.1177\/2050313x261473997","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T10:41:36Z","timestamp":1786099296000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Suspected levetiracetam drug-induced lupus in a child: A case report"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1691-8604","authenticated-orcid":false,"given":"Fiona","family":"Landells","sequence":"first","affiliation":[{"name":"Division of Dermatology, University of Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1937-1330","authenticated-orcid":false,"given":"Jeanine","family":"McColl","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Pediatrics, Alberta Children\u2019s Hospital, Calgary, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Jadhav P Kulkarni T Jadhav J et al. Levetiracetam-induced systemic lupus erythematosus. J R Coll Physicians Edinb 2021; 51(1): 58\u201360. https:\/\/doi.org\/10.4997\/jrcpe.2021.114","DOI":"10.4997\/jrcpe.2021.114"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","unstructured":"Kaya Akca U Sener S Batu ED et al. Drug-induced lupus erythematosus in childhood: case-based review. Lupus 2024; 33(7): 737\u2013748. https:\/\/doi.org\/10.1177\/09612033241245078","DOI":"10.1177\/09612033241245078"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Borchers AT Keen CL Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci 2007; 1108: 166\u2013182. https:\/\/doi.org\/10.1196\/annals.1422.019","DOI":"10.1196\/annals.1422.019"},{"key":"e_1_3_2_5_2","unstructured":"DailyMed. Levetiracetam solution. U.S. National Library of Medicine https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setif=e77162ff-0ff9-45ca95fc-da6ea24ce5a2 (2026 accessed 2 January 2026)."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Sills GJ Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology 2020; 168: 107966. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.107966","DOI":"10.1016\/j.neuropharm.2020.107966"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Surges R Volynski KE Walker MC. Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited. Ther Adv Neurol Disord 2008; 1(1): 13\u201324. https:\/\/doi.org\/10.1177\/1756285608094212","DOI":"10.1177\/1756285608094212"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Duong TA Haddad C Valeyrie-Allanore L et al. Levetiracetam: a possible new inducer of toxic epidermal necrolysis and Stevens-Johnson syndrome in 2 cases. JAMA Dermatol 2013; 149(1): 113\u2013115. https:\/\/doi.org\/10.1001\/2013.jamadermatol.266","DOI":"10.1001\/2013.jamadermatol.266"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Dar WR Sofi N Latief M et al. Levetiracetam induced drug reaction with eosinophilia and systemic symptom syndrome. Indian J Dermatol 2016; 61(2): 235. https:\/\/doi.org\/10.4103\/0019-5154.177777","DOI":"10.4103\/0019-5154.177777"},{"key":"e_1_3_2_10_2","unstructured":"Health Canada. Product monograph: levetiracetam. https:\/\/pdf.hres.ca\/dpd_pm\/00070544.PDF (2023 accessed 16 December 2025)."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Nikolaidou A Beis I Dragoumi P et al. Neuropsychiatric manifestations associated with juvenile systemic lupus erythematosus: an overview focusing on early diagnosis. Brain Dev 2024; 46(3): 125\u2013134. https:\/\/doi.org\/10.1016\/j.braindev.2023.11.008","DOI":"10.1016\/j.braindev.2023.11.008"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Natoli V Charras A Hahn G et al. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus (jSLE). Mol Cell Pediatr 2023; 10(1): 5. https:\/\/doi.org\/10.1186\/s40348-023-00161-7","DOI":"10.1186\/s40348-023-00161-7"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Appenzeller S Pereira DR Julio PR et al. Neuropsychiatric manifestations in childhood-onset systemic lupus erythematosus. Lancet Child Adolesc Health 2022; 6(8): 571\u2013581. https:\/\/doi.org\/10.1016\/S2352-4642(22)00157-2","DOI":"10.1016\/S2352-4642(22)00157-2"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Cho T Uetrecht J. How reactive metabolites induce an immune response that sometimes leads to an idiosyncratic drug reaction. Chem Res Toxicol 2017; 30(1): 295\u2013314. https:\/\/doi.org\/10.1021\/acs.chemrestox.6b00357","DOI":"10.1021\/acs.chemrestox.6b00357"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Uetrecht JP. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab Rev 1992; 24(3): 299\u2013366. https:\/\/doi.org\/10.3109\/03602539208996297","DOI":"10.3109\/03602539208996297"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"Ignacio-Mej\u00eda I Contreras-Garc\u00eda IJ Mendoza-Torreblanca JG et al. Evaluation of the antioxidant activity of levetiracetam in a temporal lobe epilepsy model. Biomedicines 2023; 11(3): 848. https:\/\/doi.org\/10.3390\/biomedicines11030848","DOI":"10.3390\/biomedicines11030848"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Ignacio-Mej\u00eda I Contreras-Garc\u00eda IJ Pichardo-Mac\u00edas LA et al. Effect of levetiracetam on oxidant-antioxidant activity during long-term temporal lobe epilepsy in rats. Int J Mol Sci 2024; 25(17): 9313. https:\/\/doi.org\/10.3390\/ijms25179313","DOI":"10.3390\/ijms25179313"},{"key":"e_1_3_2_18_2","unstructured":"Keppra\u00ae (levetiracetam) Rx only 250\u2009mg 500\u2009mg 750\u2009mg and 1000\u2009mg tablets https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021035s078s080 021505s021s024lbl.pdf (2009 accessed 8 January 2026)."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Lin T-M Chang Y-S Shen Y-C et al. Severe cutaneous adverse reactions and risk of autoimmune disease including psoriasis and inflammatory bowel disease: a cohort study. Clin Exp Dermatol 2025; 50(12): 2448\u20132455. https:\/\/doi.org\/10.1093\/ced\/llaf344","DOI":"10.1093\/ced\/llaf344"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Naranjo CA Busto U Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239\u2013245. https:\/\/doi.org\/10.1038\/clpt.1981.154","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Kessler SK McGinnis E. A practical guide to treatment of childhood absence epilepsy. Paediatr Drugs 2019; 21(1): 15\u201324. https:\/\/doi.org\/10.1007\/s40272-019-00325-x","DOI":"10.1007\/s40272-019-00325-x"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Sanghavi R Sukumaran S. Drug-induced lupus in association with ethosuximide therapy in an 11-year-old child. Pediatr Neurol 2023; 143: 95. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2023.03.012","DOI":"10.1016\/j.pediatrneurol.2023.03.012"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","unstructured":"Batra J Kaur S Kaushal S et al. Lamotrigine-induced systemic lupus erythematosus: a diagnostic dilemma. Indian Dermatol Online J 2018; 9(6): 445\u2013447. https:\/\/doi.org\/10.4103\/idoj.IDOJ_24_18","DOI":"10.4103\/idoj.IDOJ_24_18"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Gigli GL Scalise A Pauri F et al. Valproate-induced systemic lupus erythematosus in a patient with partial trisomy of chromosome 9 and epilepsy. Epilepsia 1996; 37(6): 587\u2013588. https:\/\/doi.org\/10.1111\/j.1528-1157.1996.tb00614.x","DOI":"10.1111\/j.1528-1157.1996.tb00614.x"}],"container-title":["Sage Open Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X261473997","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050313X261473997","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X261473997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T14:46:36Z","timestamp":1786286796000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050313X261473997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"alternative-id":["10.1177\/2050313X261473997"],"URL":"https:\/\/doi.org\/10.1177\/2050313x261473997","relation":{},"ISSN":["2050-313X","2050-313X"],"issn-type":[{"value":"2050-313X","type":"print"},{"value":"2050-313X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"2050313X261473997"}}